Hoth Therapeutics’ (HOTH) “Buy” Rating Reaffirmed at D. Boral Capital

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating reissued by research analysts at D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They currently have a $5.00 price target on the stock. D. Boral Capital’s price target suggests a potential upside of 163.16% from the stock’s current price.

HOTH has been the topic of several other research reports. Benchmark restated a “speculative buy” rating and set a $3.00 price objective on shares of Hoth Therapeutics in a report on Friday, October 11th. HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Hoth Therapeutics in a research report on Monday, November 4th.

Hoth Therapeutics Stock Performance

Shares of NASDAQ:HOTH opened at $1.90 on Tuesday. The stock has a market capitalization of $13.12 million, a price-to-earnings ratio of -1.44 and a beta of 0.75. Hoth Therapeutics has a 1-year low of $0.58 and a 1-year high of $3.80. The company has a 50 day moving average price of $0.86 and a 200 day moving average price of $0.85.

Hoth Therapeutics (NASDAQ:HOTH) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.01). On average, sell-side analysts expect that Hoth Therapeutics will post -1.18 EPS for the current fiscal year.

Hedge Funds Weigh In On Hoth Therapeutics

An institutional investor recently bought a new position in Hoth Therapeutics stock. Virtu Financial LLC acquired a new stake in Hoth Therapeutics, Inc. (NASDAQ:HOTH) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned 0.47% of Hoth Therapeutics as of its most recent filing with the SEC. 7.08% of the stock is currently owned by institutional investors and hedge funds.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.